Many or too many progesterone membrane receptors? Clinical implications.

Abstract

Several receptors for nongenomically initiated actions of progesterone (P4) exist, namely membrane-associated P4 receptors (MAPRs), membrane progestin receptors (mPRs), receptors for neurosteroids [GABAA receptor (GABAAR), NMDA receptor, sigma-1 and -2 receptors (S1R/S2R)], the classical genomic P4 receptor (PGR), and α/β hydrolase domain-containing protein 2 (ABHD2). Two drugs related to this field have been approved: brexanolone (Zulresso™) for the treatment of postpartum depression, and ganaxolone (Ztalmy™) for the treatment of CDKL5 deficiency disorder. Both are derivatives of P4 and target the GABAAR. Several other indications are in clinical testing. CT1812 (Elayta™) is also being tested for the treatment of Alzheimer's disease (AD) in Phase 2 clinical trials, targeting the P4 receptor membrane component 1 (PGRMC1)/S2R complex. In this Review, we highlight emerging knowledge on the mechanisms of nongenomically initiated actions of P4 and its derivatives.

• Authors: Alexandra Wendler, Martin Wehling
• Journal: Trends in endocrinology and metabolism: TEM (Trends Endocrinol Metab) Vol. 33 Issue 12 Pg. 850-868 (12 2022) ISSN: 1879-3061 [Electronic] United States
• PMID: 36384863 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2022 Elsevier Ltd. All rights reserved.

Chemical References

• Progesterone
• Receptors, Progesterone
• gamma-Aminobutyric Acid
• PGRMC1 protein, human
• Membrane Proteins
• ABHD2 protein, human
• Hydrolases

Topics

• Female
• Humans
• Progesterone (metabolism)
• Receptors, Progesterone (genetics, metabolism)
• Signal Transduction
• gamma-Aminobutyric Acid
• Membrane Proteins (metabolism)
• Hydrolases (metabolism)